Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing cancer therapies built on its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform. The company combines tumor-targeting antibodies with immune-stimulating linker-payloads to activate the innate immune system and drive anti-tumor responses. Its pipeline is centered on myeloid biology and early-stage oncology drug development, with collaborations used to expand the number of ISAC programs and potential clinical candidates. Bolt has not yet commercialized a product and has generated revenue only from collaboration agreements rather than product sales.

−452,5 %

−433,7 %

+0,1 %

3.59

3.59

— Bolt Biotherapeutics, Inc.
%
ISAC platform and pipeline programs70% Internal and partnered immune-stimulating antibody conjugate programs designed to treat cancer.
Collaboration research services30% R&D services performed under Toray, Genmab, and Innovent agreements.

Bolt's direct customers are collaboration partners rather than end patients, because the company has not yet...

  • Strategic collaboration partnersprimary

    Toray, Genmab, and Innovent-type partners fund or co-develop ISAC programs and provide antibodies, target access, or discovery capabilities.

  • Future oncology treatment providerssecondary

    Hospitals, oncologists, and cancer centers would use approved products if Bolt advances a candidate to market.

  • Payers and reimbursement decision-makerssecondary

    Insurers and health systems would determine access and reimbursement for any approved cancer therapy.

Bolt is headquartered in Redwood City, California and operates primarily from the United States, where its corporate...

  • •Headquartered in Redwood City, California, United States
  • •Primary operations and management are U.S.-based
  • •Australian subsidiary supports regional R&D and partnership activity
  • •Collaborations have an international footprint across partner organizations
  • •No country-level revenue disclosure was provided in the excerpts

Bolt's strategy is to advance its Boltbody ISAC platform into clinical candidates that can demonstrate meaningful...

01
Advance clinical and preclinical oncology programsshort-term

Clinical proof-of-concept is essential to validate the ISAC platform and create value.

02
Expand the pipeline through collaborationsmedium-term

Partnering increases the number of shots on goal without bearing all discovery costs internally.

03
Strengthen manufacturing and regulatory readinessmedium-term

Biopharma programs require scalable supply and regulatory compliance before commercialization.

Bolt faces the classic risks of a clinical-stage biopharmaceutical company: its platform is unproven, development...

critical

Unproven Boltbody ISAC platform

The company has not yet completed a successful commercialization cycle, and one early program was discontinued for insufficient efficacy.

Scope
Pipeline value and future revenue potential
Materiality
high
high

Need for additional capital

Operating losses and ongoing clinical spending mean the company may need to raise equity or partner capital before reaching self-funding status.

Scope
Dilution, financing flexibility, program continuity
Materiality
high
high

Clinical and regulatory failure

Drug candidates can fail in trials or be delayed by regulators, which would reduce or eliminate commercialization prospects.

Scope
Pipeline programs and timelines
Materiality
high
high

Third-party manufacturing dependence

The company relies on CDMOs and approved facilities for clinical and future commercial supply.

Scope
Development timelines and product supply
Materiality
medium
medium

Collaboration concentration

Revenue has come only from a small number of collaboration agreements, so changes in partner activity can materially affect results.

Scope
Collaboration revenue and pipeline expansion
Materiality
medium
Collaboration revenue recognition
Reported revenue and deferred revenue balances
Accrued clinical and manufacturing costs
Operating loss and balance sheet accruals
Deferred revenue and contract modifications
Quarterly revenue volatility

Xencor Inc

XNCR · Pharmaceutical Preparations

Summit Therapeutics Inc.

SMMT · Pharmaceutical Preparations

Bolt Projects Holdings, Inc.

BSLK · Industrial Organic Chemicals

IMAC Holdings, Inc.

BACK · Services-Specialty Outpatient Facilities, NEC

BridgeBio Oncology Therapeutics, Inc.

BBOT · Pharmaceutical Preparations

BioAtla, Inc.

BCAB · Biological Products, (No Diagnostic Substances)

: 11/08/2026